MS risk genes are transcriptionally regulated in CSF leukocytes at relapse

Multiple Sclerosis Journal

Volumn 19, Issue 4, 2013, Pages 403-410

  Jernås, Margareta ^a   Malmeström, Clas ^a   Axelsson, Markus ^a   Olsson, Caroline ^a   Nookaew, Intawat ^b   Wadenvik, Hans ^a   Zetterberg, Henrik ^c   Blennow, Kaj ^c   Lycke, Jan ^a   Rudemo, Mats ^b   Olsson, Bob ^c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Autoimmunity; Microarray; Multiple sclerosis; T cell

Indexed keywords

CXCL11 CHEMOKINE; CXCL13 CHEMOKINE; ENDOTHELIN 1; HEME OXYGENASE 1;

ADULT; ARTICLE; B LYMPHOCYTE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; INNATE IMMUNITY; LEUKOCYTE; MALE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RELAPSE; RISK; T LYMPHOCYTE;

EID: 84877867031     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512455466     Document Type: Article

References (37)

1. Sospedra M and Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005; 23: 683-747. (Pubitemid 40563183)
2. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15-23. (Pubitemid 36026342)
3. Willer CJ, Dyment DA, Risch NJ, et al. Twin concordance and sibling recurrence rates in multiple sclerosis. Proc Natl Acad Sci U S A 2003; 100: 12,877-12,882. (Pubitemid 37339993)
4. Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 476: 214-219.
5. Satoh J, Nakanishi M, Koike F, et al. T cell gene expression profiling identifies distinct subgroups of Japanese multiple sclerosis patients. J Neuroimmunol 2006; 174: 108-118.
6. Satoh J, Illes Z, Peterfalvi A, et al. Aberrant transcriptional regulatory network in T cells of multiple sclerosis. Neurosci Lett 2007; 422: 30-33. (Pubitemid 47079138)
7. Malmestrom C, Lycke J, Haghighi S, et al. Relapses in multiple sclerosis are associated with increased CD8+ T-cell mediated cytotoxicity in CSF. J Neuroimmunol 2008; 196: 159-165.
8. Riveros C, Mellor D, Gandhi KS, et al. A transcription factor map as revealed by a genome-wide gene expression analysis of whole-blood mRNA transcriptome in multiple sclerosis. PLoS One 2010; 5: e14176.
9. Achiron A, Grotto I, Balicer R, et al. Microarray analysis identifies altered regulation of nuclear receptor family members in the pre-disease state of multiple sclerosis. Neurobiol Dis 2010; 38: 201-209.
10. Brynedal B, Khademi M, Wallstrom E, et al. Gene expression profiling in multiple sclerosis: A disease of the central nervous system, but with relapses triggered in the periphery? Neurobiol Dis 2010; 37: 613-621.
11. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
12. Chomczynski P and Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159. (Pubitemid 17064313)
13. Brazma A, Hingamp P, Quackenbush J, et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 2001; 29: 365-371. (Pubitemid 34326681)
14. Diehl AD, Lee JA, Scheuermann RH, et al. Ontology development for biological systems: Immunology. Bioinformatics 2007; 23: 913-915. (Pubitemid 47049931)
15. Ashburner M, Ball CA, Blake JA, et al. Gene ontology: Tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000; 25: 25-29. (Pubitemid 30257031)
16. Chora AA, Fontoura P, Cunha A, et al. Heme oxygenase-1 and carbon monoxide suppress autoimmune neuroinflammation. J Clin Invest 2007; 117: 438-447. (Pubitemid 46203972)
17. Altmeyer PJ, Matthes U, Pawlak F, et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol 1994; 30: 977-981. (Pubitemid 24166567)
18. Kappos L, Gold R, Miller DH, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 372: 1463-1472.
19. Ghoreschi K, Bruck J, Kellerer C, et al. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med 2011; 208: 2291-2303.
20. Narushima I, Kita T, Kubo K, et al. Highly enhanced permeability of blood-brain barrier induced by repeated administration of endothelin-1 in dogs and rats. Pharmacol Toxicol 2003; 92: 21-26. (Pubitemid 36238073)
21. Shin T, Kang B, Tanuma N, et al. Intrathecal administration of endothelin-1 receptor antagonist ameliorates autoimmune encephalomyelitis in Lewis rats. Neuroreport 2001; 12: 1465-1468. (Pubitemid 32476149)
22. Reijerkerk A, Lakeman KA, Drexhage JA, et al. Brain endothelial barrier passage by monocytes is controlled by the endothelin system. J Neurochem 2012; 121: 730-737. Epub ahead of print 12 August 2011. DOI: 10.1111/j.1471-4159.2011. 07393.x.
23. Haufschild T, Shaw SG, Kesselring J, et al. Increased endothelin-1 plasma levels in patients with multiple sclerosis. J Neuroophthalmol 2001; 21: 37-38. (Pubitemid 32217099)
24. Speciale L, Sarasella M, Ruzzante S, et al. Endothelin and nitric oxide levels in cerebrospinal fluid of patients with multiple sclerosis. J Neurovirol 2000; 6 Suppl 2: S62-S66. (Pubitemid 30348914)
25. Cole KE, Strick CA, Paradis TJ, et al. Interferon-inducible T cell alpha chemoattractant (I-TAC): A novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 1998; 187: 2009-2021. (Pubitemid 28285570)
26. McColl SR, Mahalingam S, Staykova M, et al. Expression of rat I-TAC/CXCL11/SCYA11 during central nervous system inflammation: Comparison with other CXCR3 ligands. Lab Invest 2004; 84: 1418-1429. (Pubitemid 39482159)
27. Mellergard J, Edstrom M, Vrethem M, et al. Natalizumab treatment in multiple sclerosis: Marked decline of chemokines and cytokines in cerebrospinal fluid. Mult Scler 2010; 16: 208-217.
28. Szczucinski A and Losy J. CCL5, CXCL10 and CXCL11 chemokines in patients with active and stable relapsing-remitting multiple sclerosis. Neuroimmunomodulation 2011; 18: 67-72.
29. Gunn MD, Ngo VN, Ansel KM, et al. A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1. Nature 1998; 391: 799-803. (Pubitemid 28099679)
30. Bagaeva LV, Rao P, Powers JM, et al. CXC chemokine ligand 13 plays a role in experimental autoimmune encephalomyelitis. J Immunol 2006; 176: 7676-7685. (Pubitemid 43849068)
31. Krumbholz M, Theil D, Cepok S, et al. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 2006; 129: 200-211. (Pubitemid 43063771)
32. Khademi M, Kockum I, Andersson ML, et al. Cerebrospinal fluid CXCL13 in multiple sclerosis: A suggestive prognostic marker for the disease course. Mult Scler 2011; 17: 335-343.
33. Ragheb S, Li Y, Simon K, et al. Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid. Mult Scler 2011; 17: 819-829.
34. Manzo A, Vitolo B, Humby F, et al. Mature antigen-experienced T helper cells synthesize and secrete the B cell chemoattractant CXCL13 in the inflammatory environment of the rheumatoid joint. Arthritis Rheum 2008; 58: 3377-3387.
35. Ansel KM, Ngo VN, Hyman PL, et al. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 2000; 406: 309-314. (Pubitemid 30604409)
36. Serafini B, Rosicarelli B, Magliozzi R, et al. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004; 14: 164-174. (Pubitemid 38656388)
37. Matsui M, Mori KJ, Saida T, et al. The imbalance in CSF T cell subsets in active multiple sclerosis. Acta Neurol Scand 1988; 77: 202-209.